Novo Nordisk A/S

NVO· NYSE· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$47.09+0.01%

2026-08-03

Financials

Valuation Metrics

Novo Nordisk A/S's Market Cap is $208.67B. At end of 2025 it was $308.24B. Ranked #67 of 3,112 in US market (top 2%), #42 of 1,667 on NYSE (top 3%), #7 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 3%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$208.67B	US#67/3,112 Sec#7/269
Revenue	$49.54B	US#140/3,112 Sec#9/269
Net Income	$18.43B	US#25/3,112 Sec#3/269
Total Assets	$87.74B	US#200/3,112 Sec#12/269
Net Assets	$31.86B	US#154/3,112 Sec#8/269
Value
P/E	11.32x	US#330/3,112 Sec#12/269
P/B	6.55x	US#2,371/3,112 Sec#166/269
PEG	0.17x	US#275/3,112 Sec#12/269
P/S	4.21x	US#2,128/3,112 Sec#66/269
EV/EBITDA	8.13x	US#501/3,112 Sec#19/269
FCF Yield	2.25%	US#1,910/3,112 Sec#68/269
Profitability
ROE	57.85%	US#101/3,112 Sec#12/269
ROA	21.01%	US#82/3,112 Sec#18/269
Op. Margin	45.30%	US#156/3,112 Sec#8/269
Revenue Growth	23.99%	US#630/3,112 Sec#74/269
Earnings Growth	67.24%	US#463/3,112 Sec#22/269
Financial Health
Debt Ratio	175.39%	US#1,662/3,112 Sec#195/269
Total Debt	$22.97B	US#209/3,112 Sec#13/269
FCF	$4.69B	US#157/3,112 Sec#12/269
Cash	$3.31B	US#279/3,112 Sec#18/269
Current Ratio	0.79x	US#2,509/3,112 Sec#270/269
Net Debt/EBITDA	0.70x	US#903/3,112 Sec#45/269
Dividend
Div. Yield	3.80%	US#411/3,112 Sec#5/269
Div. Growth	17.27%	US#298/3,112 Sec#2/269
Performance
1Y Return	-2.29%	US#2,182/3,112 Sec#201/269
1M Return	-6.63%	US#2,384/3,112 Sec#137/269
From 52W High	-26.61%	US#2,020/3,112 Sec#146/269
1Y MDD	-56.46%	US#2,631/3,112 Sec#205/269
Trading
Volume	11,014,186 shares	US#147/3,112 Sec#10/269
Trading Value	$516M	US#207/3,112 Sec#12/269
Per Share
EPS	$3.29	US#923/3,112 Sec#28/269
BPS	$6.24	US#2,105/3,112 Sec#110/269